Hopefully soon they will announce the financial details of the MSA
Novogen has signed a Master Services Agreement (MSA) with Chiltern Oncology in relation to conduct of the phase II clinical trial of GDC-0084.
Chiltern Oncology is a leading international contract research organization, with a specialist capability in trials of novel anti-cancer agents.
The MSA details key terms of the proposed working relationship, but implementation of the study will be subject to further contractual negotiations.
Add to My Watchlist
What is My Watchlist?